Seeking Alpha

Amgen's Vectibix meets non-inferiority OS primary endpoint in Phase 3 study

  • Amgen's (AMGN) Vectibix meets its primary endpoint of non-inferiority (overall survival) to Erbitux (BMY, LLY, MKGAF.PK) in a Phase 3 trial in patients with wild-type KRAS metastatic colorectal cancer that has not responded to chemotherapy.
  • Median OS for Vectibix was 10.4 months compared to 10 months for Erbitux.
  • Median PFS for Vectibix was 4.1 months versus 4.4 months for Erbitux. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector